TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tick-borne Illness and Clothing Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being over 18 years of age~* Employee of NC Division of Forest Resources, the NC Division of Parks and Recreation, NC Wildlife Resources Commission, or NC County and Local Parks and Recreation who work in Central and Eastern North Carolina~* An average of 10 or more hours of outdoor work per week during tick season~* Self-reported prior work-related tick bites~Exclusion Criteria:~* Pregnancy~* Non-English speaking~* Known allergy to insecticides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Permethrin Impregnated Uniforms (Type: EXPERIMENTAL): Uniforms (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin.
- Placebo (Type: NO_INTERVENTION): Uniforms sent to Insect Shield, washed and refolded (no permethrin applied).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: QVA Mechanistic Efficacy Study (Receptor Effects, Etc)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~Males and females with COPD aged 40 years and above, weighing ≥45 kg and ≤100 kg, who were smokers and ex-smokers who had a smoking history of at least 10 pack years, and diagnosed with moderate to severe COPD according to GOLD 2015 criteria were included in the study. Patients with airflow limitation indicated by a post-bronchodilator FEV1/FVC \< 0.70 and by a post-bronchodilator FEV1 ≥ 30 % and \<80 % were included in the study. Post-bronchodilator refers to 1 hr (+/- 5 minutes) after sequential inhalation of 84 µg ipratropium bromide (or equivalent dose) and 400 µg salbutamol/360 µg albuterol (or equivalent dose).~Key Exclusion Criteria:~Patients with conditions which could compromise patient safety and compliance (as judged by the investigator), as well as conditions that required oxygen therapy for chronic hypoxemia, ≥25% emphysematous changes on a scan within 6 months to screening, those with lower respiratory infections within 6 weeks of screening, and patients with concomitant pulmonary disease were excluded from the study. Patients with asthma were also excluded from the study.~Pregnant or nursing (lactating) women, patients with poorly controlled Type I or Type II diabetes, patients with poor renal function, and those who were unable to use a dry powder inhaler or perform spirometry, and had contraindications to MRI were also excluded.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 110/50 mcg then Matching placebo (Type: EXPERIMENTAL): Single daily dose of 110/50 μg QVA149 for 8-10 days.
- Matching placebo then QVA149 110/50 mcg (Type: PLACEBO_COMPARATOR): Single daily dose of matching placebo for 8-10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Beta-thalassemia patients already treated with or suitable for treatment with deferoxamine 20 to 40 mg/kg/day~* Liver iron content greater than 2 mg iron/g dw as measured by liver biopsy~* Need for regular transfusions 8 or more times per year~Exclusion Criteria:~* Non-transfusional iron overload or transfusion-dependent anemias other than beta-thalassemia.~* Documented toxicity to deferoxamine~* Elevated liver enzymes in the year preceeding enrollment~* Active hepatitis B or hepatitis C~* HIV seropositivity~* Elevated serum creatinine or significant proteinuria~* History of nephrotic syndrome~* Uncontrolled systemic hypertension~* Fever and other signs/symptoms of infection within 10 days prior to start of the study~* Presence of clinically relevant cataract or previous history of clinically relevant ocular toxicity related to iron chelation~* Second or third degree AV block, clinically relevant Q-T interval prolongation, or patients requiring digoxin or other drugs that prolong the Q-T interval~* Diseases (cardiovascular, renal, hepatic, etc.)that would prevent the patient from undergoing any of the treatment options~* Psychiatric or additive disorders that would prevent the patient from giving informed consent~* History of drug or alcohol abuse within the 12 months prior to the study~* Pregnant or breast feeding patients~* Patients treated with systemic investigational drugs within 4 weeks or topical investigational drugs within 7 days before the start of the study~* Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any drug, such as gastrointestinal disease or major surgery, renal disease, difficulty voiding or urinary obstruction, or impaired pancreatic function.~* Non-compliant or unreliable patients.~* Patients unable to undergo any study procedures such as the hearing or eye tests, or the liver echocardiography.~* Inability to undergo a liver biopsy.~* Patients that would need a dose of ICL670 less than 125 mg per day.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICL670 (Type: EXPERIMENTAL): None
- Deferoxamine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Candidates for systemic therapy with moderate chronic plaque psoriasis (PsO) (with or without psoriatic arthritis) at Screening and Baseline for at least 6 months prior to Baseline defined as:~* Body Surface Area (BSA) \>= 10% and \<= 15%; and~* Psoriasis Area and Severity Index (PASI) \>= 12; and~* Static Physician Global Assessment (sPGA) = 3 (moderate) based on a 5-point scale (0 to 4).~Exclusion Criteria:~* Participant has any form of PsO other than chronic plaque PsO (e.g., pustular PsO, palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic, or guttate PsO).~* History of current drug-induced PsO or a drug-induced exacerbation of pre-existing psoriasis.~* History of active ongoing inflammatory skin diseases other than PsO and psoriatic arthritis that could interfere with the assessment of PsO (e.g., hyperkeratotic eczema).~* Prior exposure to risankizumab or apremilast.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Risankizumab (Type: EXPERIMENTAL): Risankizumab 150 mg as a single subcutaneous (SC) injection at at Baseline (Day 1) and Week 4 (Period A) and at Weeks 16, 28, and 40 (Period B).
- Apremilast (Type: EXPERIMENTAL): Participants receive apremilast 30 mg orally twice daily (BID) in Period A and re-randomized to receive either risankizumab 150 mg as a single SC injection at Weeks 16, 20, 32 in Period B or apremilast 30 mg orally BID from Week 16 up to Week 52 in Period B. For those taking apremilast in Period B, non-responders at Week 28 and Week 40 will be offered to receive risankizumab as rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* Autologous PBSC transplant patient~* English-speaking~* Planned cryopreserved PBSC infusion at the SCCA outpatient clinic~Exclusion~* History of prior autologous transplant~* Non-English-speaking~* Planned cryopreserved PBSC infusion at the UWMC inpatient unit~* Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion~* Allergy or adverse reaction to ondansetron

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ondansetron therapy (Type: EXPERIMENTAL): Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Resident Training Enhanced by New Innovations: Teleintubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Pediatric residents~Exclusion criteria:~* Residents from other departments~* Neonatology fellows~* Medical students~* Medical school Faculty

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Education for intubation skills (Type: EXPERIMENTAL): Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
- No added education for intubation skills (Type: ACTIVE_COMPARATOR): Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 yrs, male or female subject~* Subjects must have signs and symptoms of PsA ≤5 years duration at the time of the Screening Visit~* SJC AND TJC must be \>1 and ≤ 4~* For all regions, the local Regulatory Label for treatment with apremilast must be followed.~* Stable doses of protocol-allowed PsA medications~* General good health (except for psoriatic arthritis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (Note: The definition of good health means a subject does not have uncontrolled significant comorbid conditions).~* Comply with protocol-required contraception measures~* Subject meets the Classification Criteria for Psoriatic Arthritis \[CASPAR\] Criteria for PsA at the Screening visit~Exclusion Criteria:~* Prior use of \>2 csDMARD to treat PsA~* Prior exposure to a JAK-inhibitor and/or a biologic DMARD.~* Use of intra-articular (IA) or intra-muscular (IM) glucocorticoid injection within 8 weeks before the Baseline Visit.~* Use of leflunomide within 12 weeks of randomization. Subjects who stopped leflunomide and completed 11 days of treatment with cholestyramine (8 g, 3 x daily) prior to the Baseline Visit may enter the study.~* Prior use of cyclosporine.~* Prior treatment with apremilast, or participation in a clinical study, involving apremilast.~* Use of any investigational drug within 4 weeks of the Baseline Visit, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 30 mg twice daily ± NSAIDs, ≤ 1 csDMARD (Type: EXPERIMENTAL): Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is less than 6 years of age~* Severe or moderately-severe hemophilia A as defined by a baseline factor VIII level \<= 2%, documented at screening or on the basis of historical data (e.g., at hemophilia diagnosis)~* Documented medical history of at least 50 exposure days for treatment with all other factor VIII products~* Subject's parent or legally authorized representative has provided informed consent~Exclusion Criteria:~* Detectable inhibitor to factor VIII measured in the screening sample by the local or central hemostasis laboratory~* History of inhibitor to factor VIII at any time prior to screening~* Subject has any one of the following laboratory abnormalities at the time of screening:~  1. platelet count \< 100,000/mm3~ 2. hemoglobin concentration \< 10 g/dL (100 g/L)~ 3. serum creatinine \> 1.5 times the ULN for age~ 4. total bilirubin \> 2 times the ULN for age~* Subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g., platelet dysfunction secondary to uremia, liver failure, von Willebrand's Disease)~* Subject has known hypersensitivity to RECOMBINATE rAHF~* Subject is currently participating in another investigational drug study or has participated in any clinical study involving an investigational drug within 30 days of study entry~* Subject is identified by the investigator as being unable or unwilling to cooperate with study procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease~Exclusion Criteria:~* unresectable breast cancer~* ER negative primary tumor

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B (Type: ACTIVE_COMPARATOR): None
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* stage II or greater anterior vaginal prolapse requiring surgical correction~* age 21 years and older~Exclusion Criteria:~* less than Stage II anterior vaginal prolapse~* decline participation~* pregnant or contemplating future pregnancy~* prior anterior vaginal prolapse repair with biologic or synthetic graft~* active or latent systemic infection~* compromised immune system~* previous pelvic irradiation or cancer~* known hypersensitivity to polypropylene~* uncontrolled diabetes mellitus~* unable or unwilling to give valid informed consent~* unable or unwilling to comply with the protocol~* scheduled to undergo concomitant Burch colposuspension or pubovaginal sling

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Anterior Colporrhaphy (sutured repair) (Type: PLACEBO_COMPARATOR): Anterior vaginal prolapse repair with anterior colporrhaphy (no graft) using sutures.
- Perigee (grafted repair) (Type: ACTIVE_COMPARATOR): Anterior vaginal prolapse repair with graft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented S. aureus bacteremia within 2 calendar days of the first dose of study medication~Exclusion Criteria:~* Subjects with a creatinine clearance of less than 30 ml/min~* Subjects with pneumonia~* Pregnant, nursing, or lactating~* Documented history of allergy or intolerance to penicillin or vancomycin~* Subjects with osteomyelitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Patient is inadequately controlled while taking two oral antidiabetic medications~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis~* Patient required insulin therapy within the prior 3 months~* Patient has been taking Byetta (R) (exenatide) within the prior 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sitagliptin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inactivated Influenza Vaccine Effectiveness in Tropical Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female child at least 6 months of age and no older than 10 years of age (has not yet reached 11 years of age) at the enrollment visit.~* A child whose parent or guardian's primary residence, at the time of study vaccinations, is a village compound selected to receive TIV or IPV.~* Subject's parent or legal guardian is willing to provide written informed consent prior to the subject's first study vaccination.~Exclusion Criteria:~* Hypersensitivity to the active substance or any component in either TIV (which includes egg protein) or IPV. (Please see information on composition of vaccines.)~* Hypersensitivity after previous administration of any influenza or polio vaccine.~* Acute severe febrile illness. (Administration of TIV or IPV should be postponed until after recovery. Minor illnesses, such as mild upper respiratory infection, with or without low grade fever, are not reason for postponing vaccination. Acute severe febrile illness is only a temporary exclusion.)~* Any condition that, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- TIV (Type: EXPERIMENTAL): Children living in villages randomized to influenza vaccine
- IPV (Type: EXPERIMENTAL): Children living in villages randomized to polio vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete